Clinical characteristics of patients by disease
| . | CML (n = 22) . | MM (n = 10) . | MF (n = 8) . |
|---|---|---|---|
| Age, median (range), y | 53 (26-79) | 59 (44-79) | 58 (37-76) |
| ECOG performance status, median (range) | 1 (0-2) | 1 (0-1) | 1 (0-2) |
| No. prior therapies, median (range)* | 2 (1-4) | 4 (1-7) | 2 (0-5) |
| WBC count, median (range), × 109/L | 16 (1.8-66.5) | 4.4 (2.8-7.3) | 5.3 (2.1-108.4) |
| Platelet count, median (range), × 109/L | 71 (5-3895) | 232 (100-411) | 37 (7-626) |
| Hemoglobin level, median (range), g/L | 9.8 (7.1-15.4) | 10.2 (8.5-13.8) | 8.7 (6.7-13.5) |
| Rasmutations | |||
| N-ras | 0/6 | 0/3 | 0/4 |
| K-ras | 1/6 | 0/3 | 0/4 |
| CML phase | |||
| CP | 10 | NA | NA |
| AP | 6 | NA | NA |
| BP | 6 | NA | NA |
| Monoclonal protein level, median (range), g/dL | NA | 2.7 (1.3-6.2) | NA |
| Bone marrow plasma cells, median (range), % | NA | 30 (5-50) | NA |
| . | CML (n = 22) . | MM (n = 10) . | MF (n = 8) . |
|---|---|---|---|
| Age, median (range), y | 53 (26-79) | 59 (44-79) | 58 (37-76) |
| ECOG performance status, median (range) | 1 (0-2) | 1 (0-1) | 1 (0-2) |
| No. prior therapies, median (range)* | 2 (1-4) | 4 (1-7) | 2 (0-5) |
| WBC count, median (range), × 109/L | 16 (1.8-66.5) | 4.4 (2.8-7.3) | 5.3 (2.1-108.4) |
| Platelet count, median (range), × 109/L | 71 (5-3895) | 232 (100-411) | 37 (7-626) |
| Hemoglobin level, median (range), g/L | 9.8 (7.1-15.4) | 10.2 (8.5-13.8) | 8.7 (6.7-13.5) |
| Rasmutations | |||
| N-ras | 0/6 | 0/3 | 0/4 |
| K-ras | 1/6 | 0/3 | 0/4 |
| CML phase | |||
| CP | 10 | NA | NA |
| AP | 6 | NA | NA |
| BP | 6 | NA | NA |
| Monoclonal protein level, median (range), g/dL | NA | 2.7 (1.3-6.2) | NA |
| Bone marrow plasma cells, median (range), % | NA | 30 (5-50) | NA |
NA indicates not applicable.
Excluding hydroxyurea or supportive care (eg, transfusions).